Abstract
Diabetes mellitus increases cardiovascular risk, hyperglycemia (increased glycated hemoglobin) is accompanied by a higher probability of vascular catastrophe. The risk increases with increasing glycated hemoglobin.
Intensive therapy, which safely reduces hyperglycemia, also reduces the risk of microvascular complications and cardiovascular events. The target value for the treatment of hyperglycaemia, in terms of its contribution to reducing the risk of macrovascular complications, is certainly glycated hemoglobin less than 5.3% in all patients, and in the vast majority the target value is glycated hemoglobin below 4.5%.
In the ADVANCE study, close glycemic control strategies based on gliclazide MR reduced glycated hemoglobin to an average of 6.5% in a large group of patients with type 2 DM and reduced the incidence of the primary combined endpoint, severe macrovascular and microvascular events.